ANAB Company Profile and Key Details

Q: Who are the executives of ANAB?

Ms. Beth MuellerSenior Vice President of HRDr. Martin Dahl Ph.D.Senior Vice President of ResearchMr. Eric J. LoumeauChief Legal OfficerMr. Daniel R. FagaInterim Pres & Chief Executive Officer and DirectorMr. Hamza Suria M.B.A., M.Sc.AdvisoryDr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.Chief Medical OfficerMr. Dennis M. MulroyChief Financial OfficerMr. Benjamin StoneSenior Vice President of Corporation Devel.

NASDAQ : ANAB

AnaptysBio

$49.79

-17.72-26.25%

Open: 12:52 PM

60.2

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AnaptysBio, Inc. (ANAB) stock declined over -26.25%, trading at $49.79 on NASDAQ, down from the previous close of $67.51. The stock opened at $44.88, fluctuating between $44.00 and $51.43 in the recent session.

Stock Snapshot

67.51

Prev. Close

1.43B

Market Cap

Day Low

-108.24

P/E Ratio

-0.46

EPS (TTM)

-4.57

Cash Flow per Share

44.88

Open

28.75M

Number of Shares

51.43

Day High

91.42%

Free Float in %

3.31

Book Value

505.64K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2026	68.34	68.73	65.69	67.51	621.1K
Apr 16, 2026	67.22	68.27	65.83	66.90	1.3M
Apr 14, 2026	69.00	71.29	66.14	70.22	425.41K
Apr 13, 2026	70.10	73.30	68.64	68.73	579.09K
Apr 10, 2026	67.79	70.11	66.82	70.10	460.15K
Apr 09, 2026	64.78	69.13	64.61	68.54	373.09K
Apr 08, 2026	64.13	65.93	62.72	65.54	565.47K
Apr 07, 2026	62.00	62.56	60.91	62.13	295.31K
Apr 06, 2026	57.78	63.25	57.55	62.43	440.14K
Apr 02, 2026	56.19	60.14	56.03	57.68	611.62K
Apr 01, 2026	55.93	57.65	54.23	56.73	1.21M
Mar 31, 2026	57.50	60.09	55.12	55.46	810.59K
Mar 30, 2026	57.06	58.98	54.53	55.39	957.18K
Mar 27, 2026	65.16	66.28	55.61	57.40	1.35M
Mar 25, 2026	64.06	66.01	64.00	65.39	284.02K
Mar 24, 2026	62.38	64.00	60.92	63.02	224.15K
Mar 23, 2026	62.83	65.20	62.01	62.72	413.05K
Mar 20, 2026	64.47	65.71	61.61	62.37	1.46M
Mar 19, 2026	64.00	65.89	63.11	64.72	750.66K
Mar 18, 2026	67.00	67.40	64.36	64.72	1.04M

Contact Details

San Diego, CA 92121-5801

United States

https://www.anaptysbio.com 858 362 6295

About Company

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

AnaptysBio, Inc. (NASDAQ:ANAB) closed at $49.79 USD, losing -$17.72 (-26.25%) from the previous close of $67.51. The stock is currently mid-range between its 52-week high and low $17.11 and $73.30. With a market capitalization of about $1.43 billion, AnaptysBio, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 545.14 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, AnaptysBio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel R. Faga, the company employs approximately 136 people and listed since January 26, 2017. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 7.33%, SMA50 13.87%, SMA200 70.11%). The stock’s 14-day RSI is 64.61 (firm momentum), while the ATR of 3.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -2.82% below its high and over 301.07% above its low. Average 10-day trading volume of 676.70 thousand shares is slightly above the 3-month average of 526.70 thousand, indicating heightened recent market interest.

Valuation Metrics

AnaptysBio, Inc. trades at a P/E ratio of -141.78, slightly below the S&P 500 average, with a price-to-sales ratio of 8.27 and a price-to-book ratio of 50.42 reflecting a rich premium to book value. The P/FCF stands at 98.97, also above market averages. Compared to sector medians, AnaptysBio, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

AnaptysBio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$13.94. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

AnaptysBio, Inc. generated EPS of -$2.82 over the past year. Five-year average earnings growth is -7.3%. Wall Street analysts project EPS growth of 7.32% annually over the next five years. The latest quarter delivered EPS of $0.52. The next quarter is forecast at $0.86. Next year's EPS is expected at -$7.86. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 11 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $100.00 to $20.00. The high target offers 48.13% upside. The low target suggests -70.37% downside. The mean target is $67.48. This offers -0.04% upside. AnaptysBio, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -149.06%. The prior quarter beat by -10.67%. Over the last six quarters, Apple has recorded several small beats. These include 42.5% in August 05, 2024.

Shareholding & Insider Activity

AnaptysBio, Inc. has 28.75 million shares outstanding. The public float is 17.26 million shares, elevated short interest at 30.63% of float. This equals 4.79 million shares. The short ratio is 9.76 days. Institutional investors hold 121.43% of the float. Insiders own 5.76%. EcoR1 Capital, LLC holds 7.88 million shares, NODELMAN OLEG has 7.52 million shares and Novo A/S has 3.03 million shares. Over the past six months, insider transactions show net selling. They sold 120.80 thousand shares across 24 transactions.

Financial & Profitability Overview

Over the trailing twelve months, AnaptysBio generated $17.16M in revenue, or $0.64 per share. Gross margin was 86.15%, operating margin -958.27%, and net profit margin -953.66%. Returns are negative, with ROA at -36.17% and ROE at -185.71%.
On valuation metrics, AnaptysBio trades at a P/E of -141.78, P/S of 8.27 and P/B of 50.42. The current ratio is 9.07 and quick ratio is 9.07. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -530.46 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 7.81, supported by a cash flow-to-debt ratio of 0.07.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AnaptysBio posted revenue of $17.16M, down slightly from $10.29M in the prior quarter. Gross profit was $14.78M (margin 86.15%). Operating income was - $164.41M (margin -958.3%). Net income was- $163.62M (EPS - $6.08).
The company ended the quarter with $390.90M in cash and short-term investments, a total debt of $17.81M, and net debt of - $18.15M. Total assets were $452.39M, with equity of $88.10M. Financials further reflected weakness, with operating cash flow of - $120.80M, free cash flow of - $121.61M, and capital expenditures of - $807.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that AnaptysBio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.57%, with price expected at $69.92 by May 01, 2026, within a range of $64.77 to $74.77 3-Month Outlook: Projected rise of 87.78%, reaching $126.77 by July 16, 2026, with a range of $125.87 to $127.58. 1-Year Outlook: Projected gain of 7.98%, with price at $72.90 by April 16, 2027, within a range of $69.86 to $76.46.

Key Takeaways

AnaptysBio, Inc. (NASDAQ:ANAB) shares are flat -4.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows AnaptysBio, Inc. trading at a premium to the broader market with a P/E of -141.78. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $55.63, suggesting -17.6% downside. Our AI forecast model points to short-term strength (3.57% over two weeks), a medium-term rise (87.78% over three months), and a longer-term gain (7.98% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AnaptysBio, Inc. (ANAB) stock price?

AnaptysBio, Inc. (NASDAQ: ANAB) stock price is $49.79 in the last trading session. During the trading session, ANAB stock reached the peak price of $51.43 while $44.00 was the lowest point it dropped to. The percentage change in ANAB stock occurred in the recent session was -26.25% while the dollar amount for the price change in ANAB stock was - $17.72.

ANAB's industry and sector of operation?

The NASDAQ listed ANAB is part of Biotechnology industry that operates in the broader Healthcare sector. AnaptysBio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ANAB?

Ms. Beth Mueller
Senior Vice President of HR
Dr. Martin Dahl Ph.D.
Senior Vice President of Research
Mr. Eric J. Loumeau
Chief Legal Officer
Mr. Daniel R. Faga
Interim Pres & Chief Executive Officer and Director
Mr. Hamza Suria M.B.A., M.Sc.
Advisory
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
Mr. Dennis M. Mulroy
Chief Financial Officer
Mr. Benjamin Stone
Senior Vice President of Corporation Devel.

How ANAB did perform over past 52-week?

ANAB's closing price is 294.66% higher than its 52-week low of $17.11 where as its distance from 52-week high of $73.30 is -7.9%.

How many employees does ANAB have?

Number of ANAB employees currently stands at 136.

Link for ANAB official website?

Official Website of ANAB is: https://www.anaptysbio.com

How do I contact ANAB?

ANAB could be contacted at phone 858 362 6295 and can also be accessed through its website. ANAB operates from 10770 Wateridge Circle, San Diego, CA 92121-5801, United States.

How many shares of ANAB are traded daily?

ANAB stock volume for the day was 505.64K shares. The average number of ANAB shares traded daily for last 3 months was 545.14K.

What is the market cap of ANAB currently?

The market value of ANAB currently stands at $1.43B with its latest stock price at $49.79 and 28.75M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	136
Beta	0.41
Sales or Revenue	$17.16M
5Y Sales Change%	2.145%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ANAB Company Profile and Key Details

AnaptysBio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways